Skip to main content

Johnson & Johnson opens Innovation Hub in Allschwil

| News

Johnson & Johnson opens Innovation Hub in Allschwil


Johnson & Johnson has opened its first J&J Innovation Hub on the European mainland at the Switzerland Innovation Park Basel Area. This represents an extension of J&J Innovation in London and is intended to serve as a bridge to external innovations.

Sarah Mueller, Nerida Scott, Michael R Huebner and Emmanuelle Quiles (from left to right) at the opening event in Allschwil (image: Johnson & Johnson)

Johnson & Johnson has opened its first multi-purpose meeting room in its J&J office space on the Main Campus of the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft. Known as the Swiss Innovation Hub, this is the North American pharma group’s first such facility located on the European mainland.

The hub, which is managed by Michael R. Hübner, Early Innovation Partner for J&J Innovation, serves as a key extension of J&J Innovation based at the London Innovation Center. “We know true innovation takes a village and so we’re continually seeking the most promising early innovations around the world that could benefit from our insight and collaboration”, Hübner says.

Basel Area as a “top region for scientific innovation”

In this sense, the Innovation Hub is designed to promote contacts with external collaborators from “the abundant innovation ecosystem in Switzerland and neighboring countries”, as Nerida Scott, Head of J&J Innovation EMEA, writes in a LinkedIn post. During the event to mark the opening of the hub, those in attendance learned from both her and the Swiss leadership team all about “the vital role played by Basel, and Switzerland as a whole, in both biotech and medtech innovation, and Johnson & Johnson’s continued commitment to the region”. In Switzerland, Johnson & Johnson employs more than 5,700 staff across both areas. Emmanuelle Quiles, Worldwide Vice President Cardiovascular, Metabolism and Pulmonary Hypertension at Johnson & Johnson, also underlines the importance of the Basel Area. She described it as one of the “top regions for scientific innovation in the world”.

Christof Klöpper, CEO of the investment and innovation promotion agency Basel Area Business & Innovation, also discussed the opening of the Innovation Hub. He highlighted the fact that Switzerland is a globally leading region in terms of innovation in the fields of medical devices and new medicines, in addition to boasting a rich talent pool.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.